264 related articles for article (PubMed ID: 25664601)
1. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
[TBL] [Abstract][Full Text] [Related]
2. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
[TBL] [Abstract][Full Text] [Related]
3. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
Bech PR; Martin NM; Ramachandran R; Bloom SR
Ann Clin Biochem; 2014 Jan; 51(Pt 1):8-21. PubMed ID: 23939195
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.
Stridsberg M; Husebye ES
Eur J Endocrinol; 1997 Jan; 136(1):67-73. PubMed ID: 9037129
[TBL] [Abstract][Full Text] [Related]
5. Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy.
Bech P; Winstanley V; Murphy KG; Sam AH; Meeran K; Ghatei MA; Bloom SR
J Clin Endocrinol Metab; 2008 Apr; 93(4):1246-53. PubMed ID: 18211969
[TBL] [Abstract][Full Text] [Related]
6. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript.
Bech PR; Ramachandran R; Dhillo WS; Martin NM; Bloom SR
Clin Chem; 2012 May; 58(5):941-3. PubMed ID: 22361937
[No Abstract] [Full Text] [Related]
7. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
8. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
9. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
10. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A (CgA) in adrenal tumours.
Glinicki P; Jeske W; Bednarek-Papierska L; Kasperlik-Załuska A; Rosłonowska E; Gietka-Czernel M; Zgliczyński W
Endokrynol Pol; 2013; 64(5):358-62. PubMed ID: 24186592
[TBL] [Abstract][Full Text] [Related]
12. Prospective Study of Chromogranin A as a Predictor of Progression in Patients with Pancreatic, Small-Intestinal, and Unknown Primary Neuroendocrine Tumors.
Dam G; Grønbæk H; Sorbye H; Thiis Evensen E; Paulsson B; Sundin A; Jensen C; Ebbesen D; Knigge U; Tiensuu Janson E
Neuroendocrinology; 2020; 110(3-4):217-224. PubMed ID: 31578011
[TBL] [Abstract][Full Text] [Related]
13. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma.
Bílek R; Zelinka T; Vlček P; Dušková J; Michalský D; Novák K; Václavíková E; Widimský J
Physiol Res; 2017 Sep; 66(Suppl 3):S397-S408. PubMed ID: 28948824
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A: any relevance in neuroendocrine tumors?
Kidd M; Bodei L; Modlin IM
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):28-37. PubMed ID: 26627724
[TBL] [Abstract][Full Text] [Related]
15. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours.
Rehfeld JF; Broedbaek K; Goetze JP; Knigge U; Hilsted LM
Scand J Gastroenterol; 2020 May; 55(5):565-573. PubMed ID: 32352887
[No Abstract] [Full Text] [Related]
16. Characterization and plasma measurement of the WE-14 peptide in patients with pheochromocytoma.
Guillemot J; Guérin M; Thouënnon E; Montéro-Hadjadje M; Leprince J; Lefebvre H; Klein M; Muresan M; Anouar Y; Yon L
PLoS One; 2014; 9(2):e88698. PubMed ID: 24523932
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population.
Hong L; Wang Y; Zhang T; Zhang C; Wang L; Wang L; Wang Z; Zhong J
Med Sci Monit; 2020 Nov; 26():e926635. PubMed ID: 33141811
[TBL] [Abstract][Full Text] [Related]
18. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.
Miki M; Ito T; Hijioka M; Lee L; Yasunaga K; Ueda K; Fujiyama T; Tachibana Y; Kawabe K; Jensen RT; Ogawa Y
Jpn J Clin Oncol; 2017 Jun; 47(6):520-528. PubMed ID: 28334992
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma.
Bílek R; Šafařík L; Ciprová V; Vlcek P; Lisá L
Physiol Res; 2008; 57 Suppl 1():S171-S179. PubMed ID: 18271679
[TBL] [Abstract][Full Text] [Related]
20. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
